Clinical trial
Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L)
NCT00236002 · Canadian Urology Research Consortium, Other · Terminated
Key facts
| NCT number | NCT00236002 |
|---|---|
| Title | Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L ) |
| Official title | A Phase III, Double-blind, Randomized, Parallel Group, Placebo-controlled Study of Oral Fosamax, 70 mg Once a Week, for the Prevention of Androgen Deprivation Bone Loss in Non-metastatic Prostate Cancer |
| Lead sponsor | Canadian Urology Research Consortium, Other |
| Collaborators | Abbott Industry Merck Frosst Canada Ltd. |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | Alendronate |
| Enrollment | 182 |
| Start date | Jul 1, 2005 |
| Primary completion | Nov 1, 2007 |
| Completion | Aug 1, 2009 |
| First posted | Oct 12, 2005 |
| Last update posted | Aug 12, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: